Provectus Biopharmaceuticals, Inc. (PVCT) — SEC Filings
Provectus Biopharmaceuticals, Inc. (PVCT) — 35 SEC filings. Latest: ARS (Apr 30, 2026). Includes 17 8-K, 6 10-Q, 2 DEFA14A.
View Provectus Biopharmaceuticals, Inc. on SEC EDGAR
Overview
Provectus Biopharmaceuticals, Inc. (PVCT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) reported a net loss of $4,337,312 for the nine months ended September 30, 2025, a significant increase from the $2,365,241 net loss in the same period of 2024. Grant revenue decreased substantially from $602,808 in 2024 to $336,108 in 2025 for the nine-month
Sentiment Summary
Across 35 filings, the sentiment breakdown is: 1 bearish, 34 neutral. The dominant filing sentiment for Provectus Biopharmaceuticals, Inc. is neutral.
Filing Type Overview
Provectus Biopharmaceuticals, Inc. (PVCT) has filed 1 ARS, 2 DEFA14A, 6 10-Q, 17 8-K, 2 10-K/A, 2 DEF 14A, 2 10-K, 1 SC 13D/A, 1 SC 13G, 1 SC 13D with the SEC between Feb 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (35)
Risk Profile
Risk Assessment: Of PVCT's 30 recent filings, 1 were flagged as high-risk, 17 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $336,108 |
| Net Income | -$4,337,312 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $72,479 |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Pershing Edward
- Heather Raines
- Dr. Craig M. H. Smith
- Dr. Craig M. Cordola
- Dr. Craig M. Bial
Industry Context
The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like PVCT often rely on external funding, grants, and strategic partnerships to advance their drug development pipelines. The competitive landscape is intense, with established players and emerging biotechs vying for market share and investment.
Top Tags
10-Q (5) · financials (5) · material-agreement (5) · biopharmaceutical (4) · corporate-governance (4) · pharmaceuticals (4) · filing (4) · Provectus Biopharmaceuticals (4) · 8-K (3) · financial-statements (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash | $72,479 | as of September 30, 2025, down from $307,442 at December 31, 2024 |
| Working Capital Deficit | $6,193,668 | as of September 30, 2025, widened from $5,998,712 at December 31, 2024 |
| Net Loss | $4,337,312 | for the nine months ended September 30, 2025, increased from $2,365,241 in 2024 |
| Grant Revenue | $336,108 | for the nine months ended September 30, 2025, decreased from $602,808 in 2024 |
| Total Operating Expenses | $4,510,384 | for the nine months ended September 30, 2025, increased from $2,800,655 in 2024 |
| General and Administrative Expenses | $2,881,536 | for the nine months ended September 30, 2025, more than doubled from $1,358,206 in 2024 |
| Cash Used In Operating Activities | $2,456,438 | for the nine months ended September 30, 2025, increased from $2,372,083 in 2024 |
| Cash Provided By Financing Activities | $2,038,777 | for the nine months ended September 30, 2025, primarily from convertible notes |
| Common Shares Outstanding | 420,279,879 | as of November 12, 2025 |
| End of Reporting Period | 20250630 | Indicates the specific date up to which financial information is reported. |
| Filing Date | 20250814 | The date the 10-Q was officially submitted to the SEC. |
| Fiscal Year End | 2024 | The report covers the fiscal year ending December 31, 2024. |
| Reporting Period | Q1 2025 | The period covered by this 10-Q filing. |
| As of Date | 2025-03-31 | The specific date for which financial information is reported. |
| Fiscal Year | 2024 | Executive compensation and equity awards reported for this year. |
Frequently Asked Questions
What are the latest SEC filings for Provectus Biopharmaceuticals, Inc. (PVCT)?
Provectus Biopharmaceuticals, Inc. has 35 recent SEC filings from Feb 2024 to Apr 2026, including 17 8-K, 6 10-Q, 2 DEFA14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PVCT filings?
Across 35 filings, the sentiment breakdown is: 1 bearish, 34 neutral. The dominant sentiment is neutral.
Where can I find Provectus Biopharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Provectus Biopharmaceuticals, Inc. (PVCT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Provectus Biopharmaceuticals, Inc.?
Key financial highlights from Provectus Biopharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PVCT?
The investment thesis for PVCT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Provectus Biopharmaceuticals, Inc.?
Key executives identified across Provectus Biopharmaceuticals, Inc.'s filings include Pershing Edward, Heather Raines, Dr. Craig M. H. Smith, Dr. Craig M. Cordola, Dr. Craig M. Bial.
What are the main risk factors for Provectus Biopharmaceuticals, Inc. stock?
Of PVCT's 30 assessed filings, 1 were flagged high-risk, 17 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Provectus Biopharmaceuticals, Inc.?
Forward guidance and predictions for Provectus Biopharmaceuticals, Inc. are extracted from SEC filings as they are enriched.